Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Last trade$690.64
Day change-$10.01 (-1.43%)
Day range$690.01 – $708.34
Volume180,709
Market cap$55.20B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$55.2B
Price / earnings
46.69×
Price / book
29.53×
Price / sales
11.84×
EV / sales
11.98×
EV / EBITDA
33.56×
Profitability
Earnings per share
$15.01
Return on assets
31.89%
Return on equity
63.25%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.45×
Current ratio
1.19×
Quick ratio
0.88×
Cash ratio
0.16×
Cash flow
Price / cash flow
38.79×
Price / free cash flow
42.2×
Free cash flow
$1.31B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IDXX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.21B
$1.22B
$1.14B
$1.09B
$1.11B
$1.11B
$998.43M
$954.29M
Cost of revenue
$449.94M
$437.5M
$418.08M
$432.47M
$421.89M
$414.73M
$375.05M
$383.63M
Gross profit
$764.3M
$779.09M
$722.74M
$658.11M
$683.35M
$694.73M
$623.38M
$570.66M
Selling, general and administrative
$293.13M
$288.09M
$294.37M
$275.68M
$265.09M
$259.79M
$247.78M
$251.25M
Research and development
$68.82M
$65.43M
$65.79M
$66.83M
$63.42M
$61.9M
$59.06M
$57.73M
Total operating expenses
$361.95M
$353.52M
$360.15M
$342.51M
$328.51M
$321.69M
$306.85M
$308.97M
Operating income
$402.35M
$425.57M
$362.59M
$315.61M
$354.85M
$373.05M
$316.53M
$261.69M
Interest expense
-$7.46M
-$10.18M
-$7.74M
-$9.21M
-$10.66M
-$11.32M
-$7.67M
-$7.5M
Income before taxes
$399.33M
$417.22M
$355.44M
$306.98M
$344.77M
$362.35M
$310.08M
$256.39M
Income taxes
$82.18M
$78.81M
$77M
$58.79M
$70.16M
$68.36M
$67.41M
$40.24M
Net income
$317.15M
$338.41M
$278.45M
$248.19M
$274.61M
$293.99M
$242.68M
$216.15M
Net income attributable to common shareholders
$317.15M
$338.41M
$278.45M
$248.19M
$274.61M
$293.99M
$242.68M
$216.15M
EBITDA
$442.91M
$466.62M
$400.27M
$354.33M
$391.47M
$408.82M
$350.6M
$295.39M
Basic earnings per share
$4.02
$4.29
$3.50
$3.11
$3.43
$3.66
$2.98
$2.64
Diluted earnings per share
$4.01
$4.27
$3.47
$3.08
$3.40
$3.63
$2.96
$2.62
Recent news
Company coverage with links to the original publishers.
Align Technology has gained 25.4% over the past year, outperforming the S&P 500, driven by Invisalign portfolio expansion into younger patients and complex cases, plus strategic DSO partnerships. However, the stock faces headwinds from currency volatility and intense competition from traditional braces and lower-priced clear aligner alternatives. The company holds a Zacks Rank #3 (Hold) with 2026 EPS estimates revised down 1.5% to $11.12.
Envista Holdings (NVST) has gained 24% over the past year, outperforming its industry, driven by international expansion, new product launches, and strong earnings beats. The company achieved 9% adjusted EBITDA growth and 25% EPS growth. However, fierce competition, weakness in China sales, and foreign exchange headwinds pose risks to future revenue and margin expansion.
Bruker Corporation (BRKR) is well-positioned for growth driven by strong diagnostics and biosystems revenue, favorable European demand, and a $140 million cost-savings target by 2026 aimed at expanding margins by 250-300 basis points. However, uneven U.S. academic demand, macroeconomic uncertainty, and trade policy volatility present headwinds. The stock carries a Zacks Rank #3 (Hold) rating with a 3.4% earnings yield.
Labcorp Holdings (LH) has surged 48.2% year-to-date, driven by expansion in specialty testing markets, AI and automation initiatives, and six consecutive quarters of margin expansion. However, currency headwinds, intense competition, and acquisition-related execution risks could limit future growth. The company maintains a Zacks Rank #3 (Hold) with a 5% earnings yield.
Idexx Laboratories (IDXX) is identified as a compelling growth stock opportunity, earning a Zacks Rank #2 (Buy) and Growth Score of A. The animal diagnostic and healthcare company demonstrates strong fundamentals including 14.4% projected EPS growth (above the 11.6% industry average), robust year-over-year cash flow growth of 18.4%, and positive earnings estimate revisions, positioning it well for potential outperformance.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.